BPC-157 vs TB-500
Both BPC-157 and TB-500 (Thymosin Beta 4) are studied for tissue repair in preclinical models — but they work through different mechanisms, excel in different research contexts, and are often studied together. Here is the evidence-grounded comparison.
BPC-157 is a synthetic fragment of a protective protein found in gastric juice, studied primarily for gut, tendon, and vascular repair. TB-500 is a synthetic form of Thymosin Beta 4, studied for muscle, cardiac, and general cellular migration. Researchers frequently study them in combination — the Wolverine Blend (BPC-157 10mg + TB-500 10mg) is the most common stack — because their mechanisms complement rather than overlap.
At-a-glance comparison
| Attribute | BPC-157 | TB-500 (TB4) |
|---|---|---|
| Origin | Synthetic 15-amino-acid fragment of BPC (body protection compound), derived from gastric juice protein | Synthetic form of Thymosin Beta 4, a 43-amino-acid peptide found naturally in nearly all cells |
| Primary research focus | Gastric and intestinal mucosa repair, tendon-to-bone healing, vascular regeneration | Actin sequestration, cell migration, cardiac repair, muscle fiber recovery |
| Mechanism | Upregulates nitric oxide synthesis, promotes angiogenesis, modulates VEGF and FAK-paxillin pathways | Binds G-actin monomers, promotes cell motility, modulates inflammation via Laminin-5 upregulation |
| Typical preclinical half-life | Short systemic (~minutes) but local tissue persistence is longer | Moderate (~2-3 hours in circulation models) |
| Notable for | Oral bioavailability in preclinical models — orally stable in gastric environment | Systemic distribution — reaches most tissues through circulation |
| SMART MD 10mg price | $77.98 (was $114.99) | $84.98 (was $127.99) |
| Combined stack | Wolverine Blend — BPC-157 10mg + TB-500 10mg — $92.98 (was $134.99) | |
BPC-157 — what the preclinical literature shows
BPC-157 stands for "Body Protection Compound 157." It is a pentadecapeptide composed of 15 amino acids isolated from a larger protein found in human gastric juice. In preclinical research it has been studied most extensively by the research team led by Sikiric and colleagues in Zagreb, Croatia, with over 200 peer-reviewed publications across three decades of animal-model research.
Key preclinical findings (animal models)
- Gastric mucosa protection — studied for protection against indomethacin, ethanol, and NSAID-induced lesion models.
- Tendon and ligament repair — multiple rat studies examining Achilles tendon transection and medial collateral ligament injury models.
- Vascular rescue — research on reperfusion injury, venous occlusion, and angiogenesis pathway activation.
- Nervous system repair — preclinical work on traumatic brain injury and spinal cord injury animal models.
- Oral stability — unusual for peptides, BPC-157 retains activity in gastric environment in research models, enabling oral administration routes.
TB-500 (Thymosin Beta 4) — what the preclinical literature shows
TB-500 is the synthetic form of Thymosin Beta 4, a 43-amino-acid peptide that is one of the most abundant intracellular proteins. In research it functions primarily as a G-actin sequestering peptide — meaning it binds monomeric actin and modulates cytoskeletal dynamics during cell migration and wound response.
Key preclinical findings (animal and in vitro models)
- Cardiac tissue research — explored in myocardial infarction models for its role in epicardial cell activation and potential cardiomyocyte survival signaling.
- Dermal and corneal repair — studied in wound-healing models, particularly for cell migration to wound sites.
- Skeletal muscle — research into satellite cell activation and muscle fiber regeneration in injury models.
- Anti-inflammatory signaling — examined for modulation of inflammatory cytokine cascades in several tissue types.
- Systemic distribution — unlike BPC-157, TB-500 is typically administered parenterally and distributes systemically in preclinical protocols.
Why researchers study them together
BPC-157 and TB-500 are frequently combined in preclinical research protocols because their mechanisms are non-overlapping:
Different tissue targets
BPC-157 shows strong signal in gut and tendon models. TB-500 shows strong signal in cardiac, dermal, and skeletal muscle models. Together they cover more tissue types than either alone.
Complementary pathways
BPC-157 primarily engages VEGF and nitric oxide pathways. TB-500 engages actin dynamics and cell migration. The combination in research models engages both vascular and cellular repair signaling simultaneously.
Different administration flexibility
BPC-157 can be administered orally in some research protocols. TB-500 is administered parenterally. Combining allows researchers to explore route-of-administration interaction effects.
Most-studied stack
In peptide research literature, the BPC-157 + TB-500 combination is among the three most-cited stack protocols, alongside CJC-1295/Ipamorelin and Tesamorelin/Ipamorelin.
Available at SMART MD
All formulations are HPLC-tested and carry lot-specific COAs from three independent U.S. laboratories.
Frequently asked questions
BPC-157 has more published preclinical literature specifically on tendon and ligament repair models, including Achilles tendon transection studies. TB-500 has more literature on muscle and cardiac tissue. For tendon-focused research, BPC-157 is the more heavily studied compound. Many researchers use them together in the Wolverine Blend to engage both tendon (BPC-157) and adjacent muscle tissue (TB-500) pathways.
Yes — the BPC-157 + TB-500 combination is one of the most-cited stack protocols in peptide research literature. Their mechanisms are complementary: BPC-157 primarily engages vascular and gastric repair pathways (VEGF, nitric oxide), while TB-500 engages cellular migration via actin dynamics. SMART MD offers the pre-dosed Wolverine Blend (10mg of each per vial) for researchers using this stack.
BPC-157 is unusual among peptides in that it demonstrates oral bioavailability in preclinical research — it remains stable in gastric environments and is studied both orally and parenterally. TB-500 is typically administered parenterally in research protocols because it does not demonstrate the same oral stability. Researchers should consult the primary literature for their specific model.
BPC-157 and TB-500 are legal to acquire for research purposes in the United States. They are classified as research-use-only compounds — not intended for human consumption in this form. Licensed researchers and physicians may acquire them for use in preclinical research protocols. SMART MD Peptides ships only to verified research contexts.
Every SMART MD batch carries a lot-specific Certificate of Analysis (COA) from three independent U.S. laboratories. The COA documents HPLC purity, mass spectrometry molecular weight confirmation, and LAL endotoxin testing. Any batch can be verified before purchase at smartmdpeptides.com/verify. If a supplier cannot produce a lot-specific COA from independent labs, the material should be considered unverified.
Preclinical research dosing varies by model and route of administration. Published rodent studies for BPC-157 have used doses ranging from 10 μg/kg to 10 mg/kg. TB-500 animal studies have used doses ranging from 150 μg/kg to 6 mg/kg. SMART MD does not provide dosing recommendations for human use — compounds are supplied for research purposes only. Researchers should consult the primary literature and their institutional protocols.
Verify before you buy.
Every SMART MD batch is independently verified. Check the COA first. Compare it to any other supplier.